DarioHealth Q4 revenue beats estimates, net loss narrows on lower expenses

Reuters03-19
<a href="https://laohu8.com/S/DRIO">DarioHealth</a> Q4 revenue beats estimates, net loss narrows on lower expenses 

Overview

  • Digital health platform's Q4 revenue rose sequentially and beat analyst expectations

  • Q4 net loss and operating loss both narrowed and beat analyst expectations

  • Company says full-year revenue decline due to loss of single legacy client, not demand

Outlook

  • Company expects contracted ARR of $12.9 mln to contribute revenue in 2026 and 2027

  • DarioHealth expects non-GAAP operating loss to decrease by 30% in 2026

  • Company anticipates continued expansion of MSK product in international markets

Result Drivers

  • NEW ARR CONTRACTS - Sequential Q4 revenue growth driven by acceleration in new annual recurring revenue contracts from large employers and health plans

  • OPERATING EFFICIENCIES - Lower operating expenses in Q4 attributed to post-merger integration activities and increased operational efficiency

  • MSK PRODUCT DEMAND - Increased demand for musculoskeletal product in B2C market, with 36% growth in Q4

Company press release: ID:nPn9JHH1Xa

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$5.20 mln

$5.05 mln (4 Analysts)

Q4 Net Income

Beat

-$9 mln

-$14.93 mln (3 Analysts)

Q4 Operating Income

Beat

-$8.60 mln

-$8.89 mln (4 Analysts)

Q4 Gross Profit

$2.80 mln

Q4 Operating Expenses

$11.40 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for DarioHealth Corp is $20.00, about 124% above its March 18 closing price of $8.93

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment